Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...
Finanznachrichten4h
Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
Ms. Ricciardi concluded: "In addition to the substantial progress we have made with CT1812 in Alzheimer's disease, we expect to report top-line results from our Phase 2 SHIMMER study in ...
Mena FN10h
Passage Bio Reports Third Quarter 2024 Financial Results And Provides Recent Business Highlights
Passage Bio's lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow ...
After Tampa Bay’s two hurricanes, uncertainty, trauma and one lost cat
As the days stretch into months after Tampa Bay’s most destructive hurricane season in a century, the lonely slog of recovery ...